AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00963547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: \[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
Study NCT01553942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
Study NCT01553942 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Daily, Monday-Friday
Study NCT00963547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
Study NCT00963547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
Study NCT00885729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cells
Description: Stem cells or chondrocytes under a commercial available membrane
Study NCT00885729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chondrocytes
Description: Implantation of chondrocytes
Study NCT00885729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Strength exercises, neuromuscular exercises
Study NCT03665987 — intervention group
Intervention type: BEHAVIORAL
Intervention: consultation in preoperative assessment clinic
Description: The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
Study NCT01216306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Television reduction curriculum
Description: Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
Study NCT04313218 — intervention group
Intervention type: DRUG
Intervention: Carbetocin
Description: iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
Study NCT03767504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thymol
Description: Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
Study NCT03962920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline 50 MG
Description: Local instillation of drug directly to the tumour tissue
Study NCT03962920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local instillation of sterile water directly to the tumour tissue
Study NCT04980040 — intervention group
Intervention type: DRUG
Intervention: Alogliptin Benzoate
Description: Alogliptin benzoate tablets
Study NCT01479517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovacaine Mist 0.1 mL x 4 sprays
Description: Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
Study NCT01553942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Day 1 of each cycle, IV infusion over 60 minutes
Study NCT01553942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
Study NCT01553942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery to remove tumor
Study NCT02924987 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept Injection
Description: Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
Study NCT03140267 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Difficult to wean patients
Description: Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
Study NCT01479517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovacaine Mist 0.2 mL x 2 sprays
Description: Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
Study NCT01479517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovacaine Mist 0.2 mL x 1 spray
Description: Dose = 1 intranasal spray of study drug
Study NCT04582162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsplinted implants
Description: Patients received ball abutments on each implant without splinting for retaining an implant retained mandibular overdenture.
Study NCT04582162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splinted implants
Description: Patients had their implants splinted using Rhein bars with ball extension for retaining an implant retained mandibular overdenture.
Study NCT06660641 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: placebo
Study NCT04481724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gamma-linolenic acid
Description: 3 capsules per day of GLA for 24 months
Study NCT04481724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 capsules per day of placebo for 24 months
Study NCT02038023 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravaneous iron(low molecular weight iron dextran)
Description: 1000 mg of Iron dextran administered over one hour
Study NCT01456247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
Study NCT01456247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
Study NCT01456247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
Study NCT01456247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
Study NCT01456247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
Study NCT04658277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Patients in the intervention arm will take Clarithromycin 250mg daily.
Study NCT04658277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients will receive usual medical care
Study NCT00412659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for pilonidal disease, midline excision
Description: A midline excision is made for the treatment of pilonidal sinus disease.
Study NCT00412659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery for pilonidal disease, Karydakis operation
Description: A Karydakis operation is done for the treatment of pilonidal sinus disease.
Study NCT00585728 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Virtual Proctoscopy (CTVP)
Description: CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
Study NCT01206608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKY0402 + bupivacaine HCl
Description: Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
Study NCT01206608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mid-dose SKY0402 + bupivacaine HCl
Description: Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
Study NCT00039832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab (ReoPro) and Reteplase (Retavase)
Study NCT01872988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Administer Tenofovir to HCC patients who are indicated for TACE after randomization
Study NCT04289324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regular lung recruitment
Description: stepwise oxygenation-guided lung recruitment at regular (twelve hours) intervals during high frequency oscillation ventilation
Study NCT01159886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileal intubation
Description: After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed.
Study NCT02065635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maintenance with sevoflurane
Description: in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
Study NCT02065635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance with propofol
Description: in patients allocated to the propofol group, general anesthesia will be maintained with propofol
Study NCT05098808 — intervention group
Intervention type: OTHER
Intervention: Acoustic features (from signals obtained during phonation)
Description: Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient
Study NCT01849549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Experimental test about cognitive deficit of interest and standard neuropsychological tests.
Study NCT01849549 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological testing
Description: Experimental test about cognitive deficit of interest and standard neuropsychological tests.
Study NCT01849549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Anatomical, diffusion, and/or functional MRI
Study NCT01849549 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: MRI
Description: Anatomical, diffusion, and/or functional MRI
Study NCT00911144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)
Description: Intramuscular injection, administered as a single dose
Study NCT00911144 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wyeth-Lederle's Prevenar™
Description: Intramuscular injection, administered as a single dose
Study NCT00911144 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Hiberix™
Description: Intramuscular injection, administered as a single dose
Study NCT00911144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hiberix™
Description: Intramuscular injection, administered as a single dose
Study NCT02378610 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation of the gut bacterial flora in high- and low-stressed individuals
Study NCT00002852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00002852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00002852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00002852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT03170635 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Refreshing Recess program
Description: 6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
Study NCT02663206 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: peroral endoscopic myotomy
Description: peroral endoscopic myotomy
Study NCT02663206 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Botulinum toxin injection
Description: endoscopic Botulinum toxin (BTX) injection at lower esophagus
Study NCT00065351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: CC-5013 - oral - 30mg daily on days 1-21 every 28 days
Study NCT02375529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Cholecystectomy (SILC)
Description: A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
Study NCT02375529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Ports Laparoscopic Cholecystectomy (4PLC)
Description: An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation .
Study NCT00984009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
Study NCT00984009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit Juice
Description: 240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
Study NCT01638013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: Oral Tablet
Study NCT00583752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus/PSA Vaccine
Description: 1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
Study NCT01794208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin Epsilon
Study NCT00984009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
Study NCT01308853 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Macrolane
Description: Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
Study NCT01872988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer Placebo to HCC patients who are indicated for TACE after randomization
Study NCT02301052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leek topical cream
Description: Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
Study NCT02301052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo topical cream
Description: placebo topical cream 2 cc twice daily for 3 weeks
Study NCT02301052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hemorrhoid topical cream
Description: Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
Study NCT00349440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine, Refresh Plus
Description: Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.
Study NCT06143709 — intervention group
Intervention type: OTHER
Intervention: DNA sample collection
Description: Patients will be asked to provide a blood or mouth wash sample for DNA extraction
Study NCT00349440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporine, Refresh Plus
Description: Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.
Study NCT03063567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP interfaces
Description: All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
Study NCT03974945 — intervention group
Intervention type: DEVICE
Intervention: Passive-elastic prosthetic foot
Description: The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.
Study NCT03974945 — intervention group
Intervention type: DEVICE
Intervention: Powered ankle-foot prosthesis
Description: The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
Study NCT05084768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Donor-derived cell-free DNA
Description: As mentioned previously
Study NCT02565576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02603094 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clear fluid ingestion
Description: drinking of clear fluid in preoperative period
Study NCT02603094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clear fluid ingestion
Description: drinking of clear fluid in preoperative period
Study NCT02165774 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Turning OFF the neuromodulator
Description: Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
Study NCT02165774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turning ON the neuromodulator
Study NCT02151591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day
Study NCT02151591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: 12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day
Study NCT02565576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02565576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CFZ533
Study NCT04440085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Hydrochloride
Description: All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.